PRELIMINARY PROGRAMME

Von Willebrand factor and ADAMTS13 in hemostasis

09.00

Von Willebrand factor self-association role in hemostasis and thrombosis
TBA

09.30

Interactions of VWF/ADAMTS13
Jim Crawley (UK)

10.00

Modulation of ADAMTS13 conformation (open/close) in infection and other triggering conditions for TTP
TBA

10.30

Impact of cohort studies on therapeutic approaches for VWD
Jeroen Eikenboom (Netherlands)

11.00

Break

11.30

Update on 3WINTERS
Augusto B. Federici (Italy)

12.00

Acquired VWD
Giancarlo Castaman (Italy)

12.30

Mechanisms of thrombocytopenia in type 2B von Willebrand disease
TBA

13.00

Lunch

14.00

Oral Communications

Other clinical challenges of hemophilia

15.00

Ageing with hemophilia
Pier Mannuccio Mannucci (Italy)

15.30

Thrombosis in hemophilia: results from EUHASS Registry including thrombotic microangiopathies
Mike Makris (UK)

16.00

Break

Immunotolerance induction in hemophilia (Part II)

16.30

Gene-therapy-mediated tolerance induction
Valter Arruda (USA)

17.00

A working group on new concepts for ITI
Kate Pratt (USA)

17.30

Predictive markers of persistent inhibitors: which patients could benefit from ITI?
Flora Peyvandi (Italy)